Alzheimer's disease and mild cognitive impairment

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Research on the pathophysiology of Alzheimer's disease (AD) has indicated that there is an element of inflammation involved in the degenerative process. Since this element of inflammation may influence the progression of the disease and hence the symptoms, several studies have been undertaken to determine the possible efficacy of anti-inflammatories in treating AD. Atypical clinical presentations of AD occur with initial prominent symptoms in visual-spatial abilities, language, or executive functioning. However, these are much less common than the typical memory-predominate presentation. Neuropsychological testing can help determine if the subject is experiencing cognitive changes of normal aging or the earliest signs of AD or possibly mild cognitive impairment (MCI). In general, atypical antipsychotic medications are preferred in the treatment of psychosis in AD because of a better side effect profile. Implicit in a discussion of AD and MCI is knowledge about cognitive changes in normal aging.

Original languageEnglish (US)
Title of host publicationThe Wiley Handbook on the Aging Mind and Brain
PublisherWiley-Blackwell
Pages445-482
Number of pages38
ISBN (Electronic)9781118772034
ISBN (Print)9781118771778
DOIs
StatePublished - Jun 20 2017

Fingerprint

Alzheimer Disease
Inflammation
Psychotic Disorders
Antipsychotic Agents
Disease Progression
Cognitive Dysfunction
Anti-Inflammatory Agents
Language
Research

Keywords

  • Alzheimer's disease
  • Antipsychotic medications
  • Mild cognitive impairment
  • Neuropsychological testing
  • Pharmacologic treatment
  • Psychiatric symptoms

ASJC Scopus subject areas

  • Psychology(all)

Cite this

Jones, D. T., Bruns, M. B., & Petersen, R. C. (2017). Alzheimer's disease and mild cognitive impairment. In The Wiley Handbook on the Aging Mind and Brain (pp. 445-482). Wiley-Blackwell. https://doi.org/10.1002/9781118772034.ch21

Alzheimer's disease and mild cognitive impairment. / Jones, David T; Bruns, Marla B.; Petersen, Ronald Carl.

The Wiley Handbook on the Aging Mind and Brain. Wiley-Blackwell, 2017. p. 445-482.

Research output: Chapter in Book/Report/Conference proceedingChapter

Jones, DT, Bruns, MB & Petersen, RC 2017, Alzheimer's disease and mild cognitive impairment. in The Wiley Handbook on the Aging Mind and Brain. Wiley-Blackwell, pp. 445-482. https://doi.org/10.1002/9781118772034.ch21
Jones DT, Bruns MB, Petersen RC. Alzheimer's disease and mild cognitive impairment. In The Wiley Handbook on the Aging Mind and Brain. Wiley-Blackwell. 2017. p. 445-482 https://doi.org/10.1002/9781118772034.ch21
Jones, David T ; Bruns, Marla B. ; Petersen, Ronald Carl. / Alzheimer's disease and mild cognitive impairment. The Wiley Handbook on the Aging Mind and Brain. Wiley-Blackwell, 2017. pp. 445-482
@inbook{622c451a6a5e43a192081eb1748db168,
title = "Alzheimer's disease and mild cognitive impairment",
abstract = "Research on the pathophysiology of Alzheimer's disease (AD) has indicated that there is an element of inflammation involved in the degenerative process. Since this element of inflammation may influence the progression of the disease and hence the symptoms, several studies have been undertaken to determine the possible efficacy of anti-inflammatories in treating AD. Atypical clinical presentations of AD occur with initial prominent symptoms in visual-spatial abilities, language, or executive functioning. However, these are much less common than the typical memory-predominate presentation. Neuropsychological testing can help determine if the subject is experiencing cognitive changes of normal aging or the earliest signs of AD or possibly mild cognitive impairment (MCI). In general, atypical antipsychotic medications are preferred in the treatment of psychosis in AD because of a better side effect profile. Implicit in a discussion of AD and MCI is knowledge about cognitive changes in normal aging.",
keywords = "Alzheimer's disease, Antipsychotic medications, Mild cognitive impairment, Neuropsychological testing, Pharmacologic treatment, Psychiatric symptoms",
author = "Jones, {David T} and Bruns, {Marla B.} and Petersen, {Ronald Carl}",
year = "2017",
month = "6",
day = "20",
doi = "10.1002/9781118772034.ch21",
language = "English (US)",
isbn = "9781118771778",
pages = "445--482",
booktitle = "The Wiley Handbook on the Aging Mind and Brain",
publisher = "Wiley-Blackwell",
address = "United States",

}

TY - CHAP

T1 - Alzheimer's disease and mild cognitive impairment

AU - Jones, David T

AU - Bruns, Marla B.

AU - Petersen, Ronald Carl

PY - 2017/6/20

Y1 - 2017/6/20

N2 - Research on the pathophysiology of Alzheimer's disease (AD) has indicated that there is an element of inflammation involved in the degenerative process. Since this element of inflammation may influence the progression of the disease and hence the symptoms, several studies have been undertaken to determine the possible efficacy of anti-inflammatories in treating AD. Atypical clinical presentations of AD occur with initial prominent symptoms in visual-spatial abilities, language, or executive functioning. However, these are much less common than the typical memory-predominate presentation. Neuropsychological testing can help determine if the subject is experiencing cognitive changes of normal aging or the earliest signs of AD or possibly mild cognitive impairment (MCI). In general, atypical antipsychotic medications are preferred in the treatment of psychosis in AD because of a better side effect profile. Implicit in a discussion of AD and MCI is knowledge about cognitive changes in normal aging.

AB - Research on the pathophysiology of Alzheimer's disease (AD) has indicated that there is an element of inflammation involved in the degenerative process. Since this element of inflammation may influence the progression of the disease and hence the symptoms, several studies have been undertaken to determine the possible efficacy of anti-inflammatories in treating AD. Atypical clinical presentations of AD occur with initial prominent symptoms in visual-spatial abilities, language, or executive functioning. However, these are much less common than the typical memory-predominate presentation. Neuropsychological testing can help determine if the subject is experiencing cognitive changes of normal aging or the earliest signs of AD or possibly mild cognitive impairment (MCI). In general, atypical antipsychotic medications are preferred in the treatment of psychosis in AD because of a better side effect profile. Implicit in a discussion of AD and MCI is knowledge about cognitive changes in normal aging.

KW - Alzheimer's disease

KW - Antipsychotic medications

KW - Mild cognitive impairment

KW - Neuropsychological testing

KW - Pharmacologic treatment

KW - Psychiatric symptoms

UR - http://www.scopus.com/inward/record.url?scp=85049760014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049760014&partnerID=8YFLogxK

U2 - 10.1002/9781118772034.ch21

DO - 10.1002/9781118772034.ch21

M3 - Chapter

SN - 9781118771778

SP - 445

EP - 482

BT - The Wiley Handbook on the Aging Mind and Brain

PB - Wiley-Blackwell

ER -